12:49 AM EDT, 09/03/2026 (MT Newswires) -- BioArctic (BIOA-B.ST) said its partner, Eisai, received Chinese approval for the Leqembi subcutaneous autoinjector formulation as an initiation treatment for mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia. The approval was granted by the National Medical Products Administration of China following a priority review designation, according to a Thursday release. The treatment is scheduled for launch during Eisai's fiscal year ending March 31, 2027. The approved regimen for the self-administered autoinjector formulation is 500 milligrams given once weekly as two 250-milligram injections.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.